Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis
- PMID: 37052074
- DOI: 10.1093/bjd/ljad110
Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis
Erratum in
-
Correction to: Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.Br J Dermatol. 2024 May 17;190(6):e60. doi: 10.1093/bjd/ljae112. Br J Dermatol. 2024. PMID: 38518761 No abstract available.
Abstract
Background: Although chronic hand eczema (CHE) is a highly prevalent and disabling skin disease, it is currently unknown if CHE is associated with systemic inflammation.
Objectives: To characterize the plasma inflammatory signature of CHE.
Methods: Using Proximity Extension Assay technology, we assessed 266 inflammatory and cardiovascular disease risk proteins in the plasma of 40 healthy controls, 57 patients with atopic dermatitis (AD) with active lesions, 11 with CHE and a history of AD (CHEPREVIOUS_AD), and 40 with CHE and no history of AD (CHENO_AD). Filaggrin gene mutation status was also assessed. Protein expression was compared between groups and according to disease severity. Correlation analyses for biomarkers, and clinical- and self-reported variables, were performed.
Results: Very severe CHENO_AD was associated with systemic inflammation when compared with controls. Levels of T helper (Th)2- and Th1-, general inflammation and eosinophil activation markers increased with severity of CHENO_AD, primarily being significantly increased in very severe disease. Significant, positive correlations were found between markers from these pathways and severity of CHENO_AD. Moderate-to-severe but not mild AD displayed systemic inflammation. The Th2 markers C-C motif chemokine (CCL)17 and CCL13 (also known as monocyte chemotactic protein 4) were the top differentially expressed proteins in both very severe CHENO_AD and moderate-to-severe AD, showing a higher fold change and significance in AD. CCL17 and CCL13 levels further correlated positively with disease severity in both CHENO_AD and AD.
Conclusions: Systemic Th2-driven inflammation is shared between very severe CHE with no history of AD, and moderate-to-severe AD, suggesting that Th2 cell targeting could be effective in several CHE subtypes.
© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists.
Conflict of interest statement
Conflicts of interest C.B. is a consultant for Thorne HealthTech. J.P.T. is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, ASLAN Pharmaceuticals, UNION Therapeutics, Eli Lilly & Co., LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme, a speaker for AbbVie, Almirall, Eli Lilly & Co., LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron and Sanofi-Genzyme. The remaining authors declare they have no conflicts of interest.
Comment in
-
Hand eczema leaves systemic traces.Br J Dermatol. 2023 Aug 24;189(3):e56-e59. doi: 10.1093/bjd/ljad178. Br J Dermatol. 2023. PMID: 37226228 No abstract available.
-
Better understand about circulating biomarkers and disease severity of chronic hand eczema and atopic dermatitis.Br J Dermatol. 2023 Jul 7;189(1):e34. doi: 10.1093/bjd/ljad173. Br J Dermatol. 2023. PMID: 37418648 No abstract available.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
